108 related articles for article (PubMed ID: 2148034)
1. Characterization of Bay U 3405, a novel thromboxane A2/endoperoxide receptor antagonist.
Perzborn E; Fiedler VB; Seuter F; Stasch JP; Weber H; Sander E; Böshagen H; Rosentreter U
Stroke; 1990 Dec; 21(12 Suppl):IV143-5. PubMed ID: 2148034
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of platelet aggregation in vitro and ex vivo by the new thromboxane antagonist (3R)-3-(4-fluorophenylsulfonamido)-1,2,3,4-tetrahydro-9- carbazolepropanoic acid.
Seuter F; Perzborn E; Rosentreter U; Böshagen H; Fiedler VB
Arzneimittelforschung; 1989 Dec; 39(12):1525-7. PubMed ID: 2624599
[TBL] [Abstract][Full Text] [Related]
3. Effect of Bay U 3405, a new thromboxane antagonist, on collagen-induced thromboembolism in rabbits.
Seuter F; Perzborn E; Fiedler VB
Stroke; 1990 Dec; 21(12 Suppl):IV146-8. PubMed ID: 2260139
[TBL] [Abstract][Full Text] [Related]
4. Effect of BAY U 3405, a new thromboxane antagonist, on arachidonic acid induced thromboembolism.
Seuter F; Perzborn E; Fiedler VB
Adv Prostaglandin Thromboxane Leukot Res; 1991; 21A():355-8. PubMed ID: 1825569
[TBL] [Abstract][Full Text] [Related]
5. Mechanism of the protective action of Bay-u-3405, a new specific thromboxane receptor antagonist, in arachidonate-induced sudden death.
Ma XL; Karasawa A; Lefer AM
Methods Find Exp Clin Pharmacol; 1991 Mar; 13(2):105-10. PubMed ID: 1906568
[TBL] [Abstract][Full Text] [Related]
6. Antiaggregant and antivasospastic properties of the new thromboxane A2 receptor antagonist sodium 4-[[1-[[[(4-chlorophenyl)sulfonyl]amino]methyl]cyclopentyl] methyl]benzeneacetate.
Lardy C; Rousselot C; Chavernac G; Depin JC; Guerrier D
Arzneimittelforschung; 1994 Nov; 44(11):1196-202. PubMed ID: 7848331
[TBL] [Abstract][Full Text] [Related]
7. Inhibitory effects of the selective thromboxane receptor antagonist BM 13.177 on platelet aggregation, vasoconstriction and sudden death.
Patscheke H; Stegmeier K; Müller-Beckmann B; Sponer G; Staiger C; Neugebauer G
Biomed Biochim Acta; 1984; 43(8-9):S312-8. PubMed ID: 6097235
[TBL] [Abstract][Full Text] [Related]
8. Bay U 3405 inhibits cerebral vasospasm induced by authentic thromboxane A2.
Braun M; Schrör K
Stroke; 1990 Dec; 21(12 Suppl):IV152-4. PubMed ID: 2260141
[TBL] [Abstract][Full Text] [Related]
9. Antiplatelet effects of the novel thromboxane A2 receptor antagonist sodium (E)-11-[2-(5,6-dimethyl-1-benzimidazolyl)-ethylidene]-6,11- dihydrodibenz[b,e] oxepine-2-carboxylate monohydrate.
Karasawa A; Kawakage M; Shirakura S; Higo K; Kubo K; Ohshima E; Obase H
Arzneimittelforschung; 1991 Dec; 41(12):1230-6. PubMed ID: 1840011
[TBL] [Abstract][Full Text] [Related]
10. BAY u3405, a potent and selective thromboxane A2 receptor antagonist on airway smooth muscle in vitro.
McKenniff MG; Norman P; Cuthbert NJ; Gardiner PJ
Br J Pharmacol; 1991 Nov; 104(3):585-90. PubMed ID: 1839139
[TBL] [Abstract][Full Text] [Related]
11. Beneficial effects of a new potent and specific thromboxane receptor antagonist (SQ-29,548) in vitro and in vivo.
Darius H; Smith JB; Lefer AM
J Pharmacol Exp Ther; 1985 Nov; 235(2):274-81. PubMed ID: 2997428
[TBL] [Abstract][Full Text] [Related]
12. Effect of BAY U 3405, a new thromboxane antagonist, on sudden death in rabbits.
Seuter F; Perzborn E; Fiedler VB; Rosentreter U; Böshagen H
J Lipid Mediat; 1991; 3(3):283-8. PubMed ID: 1773029
[TBL] [Abstract][Full Text] [Related]
13. Receptor binding properties of the new and specific thromboxane receptor antagonist Bay U 3405.
Darius H; Michael-Hepp J; Meyer J
Agents Actions Suppl; 1992; 37():157-61. PubMed ID: 1385923
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of platelet-vessel wall interactions by thromboxane receptor antagonism in a human in vitro system: potentiation of antiplatelet effects of aspirin.
Escolar G; Albors M; Garrido M; Bioque G; Díaz Ricart M; Carretero M; Ordinas A
Eur J Clin Invest; 1998 Jul; 28(7):562-8. PubMed ID: 9726037
[TBL] [Abstract][Full Text] [Related]
15. Pharmacologic properties of KT2-962 (6-isopropyl-3-[4-(p- chlorobenzenesulfonylamino)-butyl]-azulene-1-sulfonic acid sodium salt); a new TXA2/prostaglandin endoperoxide receptor antagonist.
Kosakai K; Wakabayashi S; Sato T; Mochizuki S; Tomiyama A; Zhou Q; Satake N; Shibata S
J Cardiovasc Pharmacol; 1993 Mar; 21(3):441-7. PubMed ID: 7681506
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and absolute configuration of the new thromboxane antagonist (3R)-3-(4-fluorophenylsulfonamido)-1,2,3,4-tetrahydro-9-carbazolepropan oic acid and comparison with its enantiomer.
Rosentreter U; Böshagen H; Seuter F; Perzborn E; Fiedler VB
Arzneimittelforschung; 1989 Dec; 39(12):1519-21. PubMed ID: 2624597
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic and pharmacodynamic profiles of vapiprost, a selective, long-lasting thromboxane receptor antagonist, after single and multiple oral administration to healthy volunteers.
Uematsu T; Nagashima S; Mizuno A; Hirano K; Nakashima M
J Clin Pharmacol; 1991 Sep; 31(9):815-22. PubMed ID: 1839540
[TBL] [Abstract][Full Text] [Related]
18. Reduction of in vivo coronary artery thrombosis by the novel thromboxane antagonist (3R)-3-(4-fluorophenylsulfonamido)-1,2,3,4-tetrahydro-9- carbazolepropanoic acid.
Fiedler VB; Perzborn E; Seuter F; Rosentreter U; Böshagen H
Arzneimittelforschung; 1989 Dec; 39(12):1527-30. PubMed ID: 2624600
[TBL] [Abstract][Full Text] [Related]
19. The pharmacology of L-670,596, a potent and selective thromboxane/prostaglandin endoperoxide receptor antagonist.
Ford-Hutchinson AW; Girard Y; Lord A; Jones TR; Cirino M; Evans JF; Gillard J; Hamel P; Leveillé C; Masson P
Can J Physiol Pharmacol; 1989 Sep; 67(9):989-93. PubMed ID: 2598135
[TBL] [Abstract][Full Text] [Related]
20. Effects of the novel thromboxane antagonist Bay U 3405 on experimental coronary artery disease.
Fiedler VB; Seuter F; Perzborn E
Stroke; 1990 Dec; 21(12 Suppl):IV149-51. PubMed ID: 2260140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
